If you or your child has been diagnosed with any cancer, you or your child may be able to take part in this study. This study will collect and store samples from you or your child so that researchers can use these samples and learn more about the disease.

Are you a woman aged 65 years or older with early stage breast cancer? Have you or are you scheduled to receive a lumpectomy? If so you may be able to take part in a clinical trial to measure quality of life after breast cancer treatment.

If you or your child has been diagnosed with acute lymphoblastic leukemia (ALL), you or they might be able to take part in a research study. This study aims to understand why there are differences in outcomes in adolescents and young adults treated for ALL.

If you are receiving your cancer treatment at an infusion space in North Carolina Basnight Cancer Hospital (NCBCH), you may be able to take part in a research study. This study aims to understand your satisfaction and experience in the infusion spaces during your treatment.

Do you have asymptomatic multiple myeloma, also known as smoldering multiple myeloma? You may be able to take part in a research study to help us learn more about the effectiveness of a drug called daratumumab in combination with lenalidomide and steroids.

Have you been diagnosed with high-risk non-muscle invasive bladder cancer which has not responded to initial treatment with Bacillus Calmette-Guerin (BCG)? If so, you may be able to take part in a research study evaluating the safety of adding the study drug called pembrolizumab to an existing treatment option for bladder cancer patients.

Do you have relapsed or refractory multiple myeloma? Have you received at least one type of treatment? If so, you may be able to take part in a research study looking at the the safety of giving an investigational medication to patients with multiple myeloma.

Have you been diagnosed with oropharyngeal (tonsil or tongue base) cancer. If so, you may be able to take part in a research study testing markers to determine who may be appropriate for less aggressive therapy and markers to determine if recurrent tumors can be detected earlier.

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.

Do you currently have a cancerous tumor that has advanced or progressed? Are you currently not on any standard of care treatment options? If so, you may be able to take part in a research study to see if a new drug may be able to slow the growth of your cancer. Travel reimbursement and compensation provided.